Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zigakibart in IgA Nephropathy
NCT07146906Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Mar 2026
- Primary completion
- Jul 2030
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of zigakibart in immunoglobulin A nephropathy (IgAN), sponsored by Novartis. Started Mar 2026; status: recruiting.
02
Drugs
zigakibart
03
Conditions
immunoglobulin A nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07146906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07146906.